🇺🇸 FDA
Patent

US 8309525

Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof

granted A61KA61K38/1709A61K38/1716

Quick answer

US patent 8309525 (Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof) held by The Regents of the University of California expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Nov 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K38/1709, A61K38/1716, A61P, A61P3/10